Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Wan Keung R Wong


Wan Keung R Wong

Hong Kong University of Science and Technology, Hong Kong

Biography

Wan Keung R Wong graduated from UBC in 1986 and worked first as Postdoctoral Fellow and subsequently as Research Scientist at Allelix Biopharmaceuticals for four years, joined Hong Kong University of Science and Technology (HKUST) in 1990 and is currently appointed as Associate Professor of Division of Life Science at HKUST. Concurrently, he serves as Chairman of Gene-vinate Limited, which was founded in October 2006 and is currently a member/company of the HKUST Entrepreneurship Program. He has been involved in both basic and applied research activities in the field of Biotechnology. His expertise lies in molecular biology, development of microbial expression systems, and cost-effective production of recombinant proteins for commercial applications. He was a pioneer in the development of novel Escherichia coli excretion and intein-mediated expression systems for efficient expression of valuable proteins, e.g. human epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF). These factors have been employed by WK’s team as active ingredients in skincare products for applications. For example, EGF has been used to effectively treat hard-to-heal wounds including diabetic foot ulcers, bedsores and others. In addition to publishing these important results in the June 2003 issue of Diabetes Care, a PCT patent, covering USA, PRC, Taiwan, Europe, and Hong Kong has been granted for these novel findings. Under the leadership of WK, GVN has developed many lines of healthcare and cosmetic products for commercial applications. Because of his enthusiasm in biotechnological R&D, and commercialization of the resulting outputs, WK has recently been nominated by China Daily as one of the world’s 80 eminent Chinese entrepreneurs in 2014. In addition, GVN has recently been elected by Mediazone Group as the most innovative Biotechnology Group in Hong Kong in 2015.

Abstract

Abstract : Recombinant production of human skin growth factors for effective treatments for hard-to-heal wounds